证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |-----------------------|-------------------------|---------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中金公司 高峥、唐卓菁；申万宏源 何婧雯、张颢译；国海证 | | | | 券 梁欢；华创证券 蔡春根；大成基金 李博、韩创；银华基金 | | 人员姓名 | 王丽敏。 | | | 时间 | 2016 年 2 月 18 | 日 | | 地点 | | 江苏澳洋科技股份有限公司会议室 | | 上市公司接待人 员姓名 | 马科文、季超 | | | 投资者关系活动 | 一、粘胶短纤 ...

Group 1: Viscose Staple Fiber Business - The market outlook for the viscose market is optimistic, with the Xinjiang production base returning to normal operations, which helps stabilize the profitability of viscose staple fiber by reducing cyclical fluctuations [3]. Group 2: Health Industry Development - The company has established a medical service system centered around Aoyang Hospital, with branches including Yangshe, Sanxing, and Shunkang, focusing on basic medical services while incorporating specialized features [3]. - Aoyang Hospital is a JCI accredited facility and was recognized as "2015 National Excellent Private Hospital" and "2015 Most Valuable Private Hospital" [3]. - The company aims to accelerate brand development in the health sector, enhance specialized departments, and improve the competitiveness in the East China region while advancing the construction of an information-based medical platform [3]. - In the pharmaceutical distribution sector, Aoyang Health has developed a large modern pharmaceutical distribution network covering East China and serving the entire country, becoming one of the largest private pharmaceutical logistics enterprises in the region [3]. - The implementation of a private placement will support the development of the health industry, enhance the technical level of medical services, and facilitate the company's expansion beyond Zhangjiagang into a chain operation model [3].

江苏澳洋健康产业股份有限公司 2022 年第三季度报告 证券代码：002172 证券简称：澳洋健康 公告编号：2022-52 江苏澳洋健康产业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 1 江苏澳洋健康产业股份有限公司 2022 年第三季度报告 （二） 非经常性损益项目和金额 适用 □不适用 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元 ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥1.035 billion, a decrease of 41.49% compared to the same period last year[20]. - The net profit attributable to shareholders was approximately ¥46.03 million, a significant turnaround from a loss of ¥765.12 million in the previous year, representing a 106.02% increase[20]. - The net cash flow from operating activities was negative at approximately -¥201.05 million, a decline of 530.82% compared to the previous year[20]. - Basic and diluted earnings per share were both ¥0.06, compared to -¥0.99 in the same period last year, marking a 106.06% improvement[20]. - The weighted average return on equity was 53.41%, a substantial increase of 187.69% from -134.28% in the previous year[20]. - Total assets at the end of the reporting period were approximately ¥2.979 billion, down 22.09% from the end of the previous year[20]. - The net assets attributable to shareholders increased by 72.88% to approximately ¥109.18 million compared to the previous year[20]. - The company achieved a revenue of approximately CNY 1.04 billion, a decrease of 41.49% compared to the previous year's CNY 1.77 billion, primarily due to the termination of the chemical fiber business[40]. - Operating costs decreased by 44.00% to CNY 906.17 million, reflecting the cessation of the chemical fiber operations[40]. - The company reported a net cash inflow from investment activities of CNY 864.39 million, a significant increase of 189.41% due to proceeds from the sale of chemical fiber assets[40]. Business Transformation - The company has fully transformed its main business to health services, with a focus on medical services that have strong anti-cyclical properties[28]. - The company completed the sale of all assets related to differentiated viscose short fibers and ordinary viscose fibers, marking a full transition to the health industry[38]. - The company is focusing on transforming its business towards the medical health sector, aiming for business transformation and industrial upgrading[68]. - The company plans to explore integrated medical and rehabilitation services following the merger of the Port City Rehabilitation Hospital with Aoyang Hospital[61]. - The company has established Jiangsu Aoyang Biotechnology Co., Ltd. to explore sales in functional foods and health products, seeking new growth channels[38]. Strategic Initiatives - The company plans to accelerate brand building in the health sector and enhance specialty care cultivation, aiming to strengthen its competitive position in East China[36]. - The company aims to build a high-level research institute that integrates medical, teaching, and research functions, with a focus on oncology[34]. - The company plans to continue expanding its healthcare services and logistics operations as part of its strategic transformation[41]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[144]. - The company has initiated a strategic partnership with a leading technology firm to enhance its product offerings and improve operational efficiency[160]. Market and Industry Outlook - The company is positioned to benefit from the growing demand for medical services driven by population aging and chronic disease prevalence, with a significant growth potential in the health service industry[32]. - The government policies under the "14th Five-Year Plan" present greater opportunities for the health industry, indicating a favorable environment for the company's continued growth[34]. - Future guidance indicates an expected revenue growth of 20% for the second half of 2022, driven by new product launches and market expansion strategies[160]. Risks and Challenges - The company has acknowledged risks related to national policies affecting the healthcare industry, urging investors to remain aware of investment risks[3]. - The company is facing macroeconomic risks that could impact consumer demand and purchasing power, particularly in the context of a slowing economy[72]. - The company is also addressing competition risks in the healthcare sector, particularly from private hospitals entering the market[72]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The total number of shares is 776,481,362, with 10,749,002 shares repurchased, representing 1.38% of total shares[119]. - The largest shareholder, Aoyang Group, holds 30.31% of the shares, totaling 235,349,599 shares, with 66,686,543 shares pledged[122]. Financial Stability - Total liabilities decreased from CNY 3,772,380,051.34 to CNY 2,881,266,113.23, a reduction of approximately 24%[138]. - The company's cash and cash equivalents increased from CNY 982,576,248.53 to CNY 1,139,317,934.85, an increase of about 16%[136]. - The equity attributable to the parent company increased from CNY 63,155,721.88 to CNY 109,182,532.10, an increase of approximately 73%[138]. Social Responsibility - The company has actively engaged in social responsibility initiatives, including free medical consultations in communities[82]. - The company has implemented various public welfare projects, receiving positive feedback from the community[82]. Compliance and Governance - The semi-annual financial report was not audited[88]. - No major litigation or arbitration cases were reported, with a total of 1,852.44 million yuan involved in minor cases[92]. - The company has not encountered any major changes in the use of raised funds, and the overall use of funds is proceeding normally[59].

Financial Performance - The company's revenue for Q1 2022 was ¥643,577,490.50, a decrease of 34.01% compared to ¥975,222,843.19 in the same period last year[3] - Net profit attributable to shareholders was ¥32,498,869.97, down 9.91% from ¥36,074,414.82 year-on-year[3] - The net profit after deducting non-recurring gains and losses surged by 10,665.15% to ¥39,746,660.40 from ¥369,216.19 in the previous year[3] - The company reported a 49.03% decrease in main business income due to the divestiture of fiber assets[8] - Net profit for Q1 2022 was CNY 32,791,964.27, a decline of 10% from CNY 36,334,858.20 in Q1 2021[21] - Earnings per share for Q1 2022 were CNY 0.04, down from CNY 0.05 in Q1 2021[21] Cash Flow - The net cash flow from operating activities was -¥323,103,011.47, a decline of 263.58% compared to ¥197,519,222.99 last year[3] - Cash inflow from operating activities totaled CNY 750,511,190.57, while cash outflow was CNY 1,073,614,202.04, resulting in a significant cash flow deficit[24] - The net cash flow from investment activities was 761,728,828.43 CNY, compared to a negative cash flow of -197,318,455.24 CNY in the previous period[25] - The total cash inflow from financing activities amounted to 981,994,393.90 CNY, while cash outflow for financing activities was 1,297,818,721.03 CNY, resulting in a net cash flow of -315,824,327.13 CNY[25] - The cash and cash equivalents at the end of the period totaled 255,243,824.48 CNY, an increase from the beginning balance of 132,458,055.32 CNY[25] - The net increase in cash and cash equivalents for the period was 122,785,769.16 CNY, contrasting with a decrease of -269,189,358.79 CNY in the previous period[25] Assets and Liabilities - Total assets decreased by 24.60% to ¥2,882,794,247.05 from ¥3,823,219,194.07 at the end of the previous year[3] - The company's total assets decreased from 3,823,219,194.07 CNY at the beginning of the year to 2,882,794,247.05 CNY at the end of the reporting period[16] - Total current liabilities decreased from 3,455,221,028.57 CNY to 2,520,476,148.47 CNY[17] - The total non-current liabilities decreased from 317,159,022.77 CNY to 278,686,991.58 CNY[17] - Shareholders' equity increased by 51.46% to ¥95,654,591.85 from ¥63,155,721.88 at the end of the previous year[3] Shareholder Information - The total number of common shareholders at the end of the reporting period is 76,083[11] - The largest shareholder, Aoyang Group Co., Ltd., holds 30.31% of shares, totaling 235,349,599 shares, with 66,686,547 shares pledged[12] Business Strategy and Operations - The company is undergoing a strategic business transformation by divesting from chemical fiber operations to focus on the medical health sector[13] - The company is actively pursuing market expansion strategies, particularly in the healthcare sector, as part of its business transformation[13] - The company has ongoing research and development efforts in new products and technologies, although specific details were not disclosed in the report[12] Operating Costs - Operating costs decreased by 32.31% year-on-year, attributed to the reduction in costs from the fiber asset divestiture[9] - Total operating costs for Q1 2022 were CNY 651,936,595.48, down 32.5% from CNY 967,477,741.20 year-over-year[19] Other Financial Metrics - The company experienced a 100% decrease in asset disposal income, as no such income was recorded in the current period[9] - The company reported a credit impairment loss of CNY 41,922,470.58, compared to a gain of CNY 2,650,997.33 in the previous year[21] - The company recorded a loss of CNY 142,691.76 from investment activities, compared to a loss of CNY 119,663.24 in the previous year[21] - The company achieved a cash inflow of CNY 950,803,465.62 from the disposal of fixed assets, a significant increase from CNY 76,177,376.75 in the same period last year[24] Audit and Compliance - The company did not conduct an audit for the first quarter report[27]

Financial Performance - The company's operating revenue for 2021 was approximately ¥3.03 billion, a decrease of 1.77% compared to ¥3.08 billion in 2020[20]. - The net profit attributable to shareholders for 2021 was approximately -¥1.04 billion, representing a decline of 126.35% from -¥458.99 million in 2020[20]. - The net cash flow from operating activities for 2021 was -¥33.47 million, a significant decrease of 126.70% compared to ¥125.33 million in 2020[20]. - The total assets at the end of 2021 were approximately ¥3.82 billion, a decrease of 40.51% from ¥6.43 billion at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥63.16 million, down 93.37% from ¥952.33 million at the end of 2020[20]. - The basic earnings per share for 2021 was -¥1.34, a decline of 127.12% compared to -¥0.59 in 2020[20]. - The weighted average return on net assets for 2021 was -240.00%, a decrease of 201.16% from -38.84% in 2020[20]. - The company reported a total revenue of 1,940.1 million RMB for the year 2021, with a significant increase of 25.39% compared to the previous year[156]. Business Strategy and Focus - The company is in the process of divesting its assets related to the production and sales of differentiated viscose short fibers and ordinary viscose fibers, focusing fully on the healthcare business thereafter[19]. - The company aims to optimize asset adjustments and achieve upgrades in the health industry, focusing on the integration of medical and health services[84]. - The company plans to explore the "light medical beauty" business and expand its coverage in the medical beauty sector[84]. - The company is focused on expanding its healthcare services and product offerings in the market[99]. - The company aims to enhance its brand in the healthcare sector and expand its specialty services, focusing on building a competitive edge in the East China region[40]. Market and Industry Trends - The healthcare industry in China is experiencing rapid growth, driven by increased medical consumption demand and a rising elderly population, with 18.17% of the population aged 60 and above as of 2020[32][33]. - The average annual increase in chronic disease cases in China has reached nearly double over the past decade, significantly boosting the demand for medical services[33]. - The company is positioned to benefit from national policies encouraging private healthcare investment, which aim to enhance the quality and efficiency of medical services[34]. Revenue Segmentation - The medical services segment generated revenue of approximately CNY 948.12 million, representing a growth of 10.54% from CNY 857.69 million in 2020, accounting for 31.30% of total revenue[46]. - The pharmaceutical logistics segment contributed approximately CNY 1.03 billion, a slight increase of 1.58% from CNY 1.01 billion in 2020, making up 33.92% of total revenue[46]. - The chemical fiber segment saw a revenue decline of 13.25%, with total revenue of approximately CNY 1.05 billion compared to CNY 1.21 billion in 2020, representing 34.78% of total revenue[46]. Operational Efficiency - Operating cash inflow increased by 15.83% to ¥2,945,927,809.34, while operating cash outflow rose by 23.22% to ¥2,979,393,388.92[59]. - The company has established a modernized pharmaceutical distribution network covering East China, positioning itself as one of the largest private logistics enterprises in the region[42]. - The new logistics center is designed to meet annual storage and logistics service needs of approximately CNY 2 to 2.5 billion, enhancing operational efficiency and service quality[39][42]. Governance and Management - The company has established a governance structure in compliance with relevant laws and regulations, ensuring independent operations from its controlling shareholder[92]. - The company is committed to risk management and ensuring legal and efficient operations during its transformation[84]. - The company has implemented a comprehensive information disclosure and investor relations management system to ensure transparency[90]. - The company reported a total of 1,153,840 shares held by its directors and supervisors at the beginning of the reporting period[96]. Environmental Responsibility - The company has a daily wastewater treatment capacity of 60,000 tons, with treated water meeting the national discharge standards[134]. - The company has implemented all pollution prevention facilities, with stable operation of wastewater and exhaust gas treatment systems[132]. - The company has established an emergency response plan for environmental incidents, effective from January 8, 2020[133]. Legal and Compliance - The current auditor is Lixin Certified Public Accountants with an audit fee of 1.5 million CNY, and they have been serving for 7 years[145]. - The company has not reported any major deficiencies in non-financial reporting during the reporting period[126]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[157]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue increase of 10% to 1.32 billion RMB[103]. - New product launches are expected to contribute an additional 200 million RMB in revenue over the next fiscal year[103]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB for potential deals[103].

Financial Performance - The company's revenue for Q3 2021 was CNY 660,587,909, a decrease of 15.79% compared to the same period last year[3]. - The net profit attributable to shareholders was a loss of CNY 145,945,060.70, down 51.95% year-on-year[3]. - Total profit decreased by 374.4% year-on-year, primarily due to impairment provisions related to the sale of viscose-related asset groups[8]. - Net profit attributable to the parent company decreased by 345.58% year-on-year, driven by increased impairment provisions from asset sales[8]. - Net loss for Q3 2021 amounted to ¥935,289,063.97, compared to a net loss of ¥213,990,094.33 in Q3 2020, indicating a significant decline in profitability[20]. - The total comprehensive income for the period was -911,062,744.47 CNY, compared to -204,465,903.76 CNY in the previous period, indicating a significant decline[21]. - Basic and diluted earnings per share were both -1.17 CNY, down from -0.26 CNY in the same period last year[21]. Cash Flow - The net cash flow from operating activities was negative CNY 275,502,278.35, representing a decline of 1,213.21% compared to the previous year[3]. - Cash received from sales of goods and services increased by 46.16% year-on-year, attributed to higher sales volume and prices of viscose products[8]. - Cash paid for purchasing goods and services increased by 99.32% year-on-year, due to a rise in cash payments for raw material procurement[8]. - Cash inflow from operating activities totaled 2,192,959,888.41 CNY, an increase from 1,609,782,565.62 CNY in the previous period[24]. - The total cash outflow from operating activities was 2,468,462,166.76 CNY, compared to 1,585,034,183.39 CNY in the previous period[24]. - Cash flow from investing activities generated a net inflow of 163,518,335.51 CNY, compared to a net outflow of -200,524,727.94 CNY in the previous period[24]. - Cash flow from financing activities resulted in a net inflow of 79,504,251.23 CNY, down from 135,102,131.89 CNY in the previous year[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,312,266,850.85, a decrease of 17.34% from the end of the previous year[3]. - Total current assets increased to ¥4,291,155,642.53 as of September 30, 2021, from ¥2,876,325,243.35 at the end of 2020, reflecting a growth of 49.2%[15]. - Total liabilities decreased to ¥5,279,253,409.20 from ¥5,458,300,814.89, a reduction of 3.3%[16]. - The company's equity totaled CNY 968,302,505.62, with a capital reserve of CNY 1,151,303,231.24 and retained earnings showing a deficit of CNY 968,394,932.52[29]. - Total assets amounted to CNY 6,426,603,320.51, with current assets at CNY 2,876,325,243.35 and non-current assets at CNY 3,550,278,077.16[28]. Expenses - Other business income increased by 68.06% year-on-year, attributed to higher sales of raw materials and by-products[7]. - Other business costs rose by 126.12% year-on-year, also due to increased sales of raw materials and by-products[7]. - Research and development expenses were reported as zero for the current period, indicating no R&D activities[7]. - The company reported a significant increase in management expenses to ¥241,353,491.34, up from ¥200,849,323.32, reflecting a rise of 20.2%[20]. - Operating profit decreased by 194.93% year-on-year, mainly due to increased asset impairment provisions[8]. Impairment and Provisions - Asset impairment losses increased by 5624.44% year-on-year, primarily due to higher provisions for inventory and fixed assets[8]. - The company experienced a 3160.72% increase in advance receipts, reflecting pre-sales of certain assets during the reporting period[7]. - Investment income decreased by 100.62% compared to the same period last year, mainly due to a reduction in financial management income[8]. Other Information - The company did not undergo an audit for the third quarter report[31]. - The report indicates a significant investment in fixed assets, totaling CNY 3,267,306,561.25, with a decrease of CNY 166,175,115.23 compared to the previous period[28]. - The report was released on October 28, 2021, and is the first to apply the new leasing standards retrospectively[30].

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,769,705,394.73, representing a 31.33% increase compared to CNY 1,347,519,285.66 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was a loss of CNY 765,117,683.76, a significant decline of 605.71% from a loss of CNY 108,417,869.17 in the previous year[19]. - The net cash flow from operating activities decreased by 65.00%, amounting to CNY 46,666,671.47 compared to CNY 133,324,764.61 in the same period last year[19]. - The total assets at the end of the reporting period were CNY 5,568,605,108.25, down 13.35% from CNY 6,426,603,320.51 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company decreased by 80.34%, totaling CNY 187,217,018.45 compared to CNY 952,334,702.21 at the end of the previous year[19]. - The basic and diluted earnings per share were both CNY -0.99, reflecting a decrease of 607.14% from CNY -0.14 in the same period last year[19]. - The weighted average return on net assets was -134.28%, a decline of 126.29% from -7.99% in the previous year[19]. - The company reported a significant decline in performance due to impairment provisions related to the assets of its subsidiary, Funing Aoyang Technology, which impacted the semi-annual results compared to the previous year[51]. - The company reported a net loss of CNY 1,733,512,616.28 for the first half of 2021, compared to a loss of CNY 968,394,932.52 in the previous period[125]. - The total comprehensive income for the period was CNY -1,457,032,970.61, compared to CNY 77,581,480.86 in the previous period, showing a significant decline[137]. Strategic Changes - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has signed an asset sale agreement with Sedley China to divest its viscose staple fiber business, which has been approved by shareholders and regulatory authorities[29][32]. - The company plans to focus on health-related developments following the divestiture of its viscose staple fiber business, indicating a strategic shift in operations[35]. - The company is focusing on transforming its business towards the healthcare sector, moving away from chemical fiber operations[51]. - The company aims to shift its focus entirely to the medical and health sector, achieving business transformation and industrial upgrading[100]. - The company is exploring new strategies for growth, including potential mergers and acquisitions in the healthcare industry[81]. Healthcare Sector Focus - The company aims to enhance its brand in the healthcare sector and expand its specialty services, focusing on building a competitive edge in the East China region[30]. - The company’s hospital has been recognized as a tertiary comprehensive hospital and has passed JCI re-evaluation, enhancing its reputation in the healthcare field[31]. - The company is committed to the rapid development of its oncology services and aims to create a high-level research institute integrating medical education and research[28]. - The company’s medical service business is expected to maintain stable profitability due to the growing demand for healthcare services in China[28]. - The company is focusing on expanding its healthcare services, including orthopedics, oncology, and urology, while also developing aesthetic medicine, health management, and physical examination services to diversify growth points[55]. Financial Position and Assets - The total liabilities decreased slightly to CNY 5,386,247,203.68 from CNY 5,458,300,814.89, a reduction of about 1.3%[124]. - The company’s total non-current assets decreased to CNY 2,653,667,984.79 from CNY 3,550,278,077.16, a decline of about 25.3%[123]. - The company’s total equity decreased to CNY 182,357,904.57 from CNY 968,302,505.62, a significant drop of approximately 81.2%[125]. - The company’s total liabilities amounted to ¥2,432,114,802.36, slightly down from ¥2,435,141,154.92 in the previous year[130]. - The total equity decreased to ¥179,676,534.70 from ¥1,636,709,505.31, reflecting a substantial drop in shareholder value[130]. Cash Flow and Investments - The net cash flow from investing activities was ¥298,675,494.44, a recovery from a negative cash flow of ¥333,324,393.96 in the previous year[34]. - The company reported a significant decrease in cash flow from operating activities, down 65.00% to ¥46,666,671.47 from ¥133,324,764.61 in the previous year[34]. - Cash inflow from investment activities totaled CNY 606,451,032.70, compared to CNY 542,035,406.67 in the previous year, indicating an increase of about 11.9%[139]. - The net cash flow from financing activities was negative at CNY -288,582,465.05, contrasting with a positive CNY 154,016,007.72 in the first half of 2020[140]. Environmental Compliance - The company has a daily wastewater treatment capacity of 60,000 tons, with treated water meeting national discharge standards[67]. - The company has implemented automatic and manual monitoring for wastewater and flue gas emissions, ensuring compliance with environmental regulations[67]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[68]. Shareholder Information - The total number of shares after the recent changes was 776,481,362, with 99.54% being unrestricted shares[104]. - The largest shareholder, Aoyang Group Co., Ltd., holds 30.31% of the shares, totaling 235,349,599 shares[108]. - The company repurchased 10,749,002 shares, accounting for 1.38% of the total shares[109]. - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[112]. Risk Factors - The company acknowledged risks related to fluctuations in raw material prices and domestic and international demand[4]. - The company faces macroeconomic risks that could impact consumer demand and purchasing power, particularly in the context of a slowing economy[54]. - The healthcare industry is experiencing increased competition due to the entry of private capital and reforms in the medical system, which may affect the company's market position[54]. Accounting and Reporting - The semi-annual financial report was not audited[74]. - The company’s financial statements comply with the accounting standards issued by the Ministry of Finance, reflecting its financial status accurately as of June 30, 2021[179]. - The company’s business cycle is defined as 12 months, aligning with its accounting period from January 1 to December 31[180][181].

Financial Performance - The company's operating revenue for Q1 2021 was ¥975,222,843.19, representing a 53.75% increase compared to ¥634,283,585.15 in the same period last year[7] - Net profit attributable to shareholders was ¥36,074,414.82, a significant turnaround from a loss of ¥121,844,721.30 in the previous year, marking a 129.61% improvement[7] - Basic earnings per share improved to ¥0.05 from a loss of ¥0.16, indicating a 131.25% increase[7] - Total revenue increased by 54% year-on-year, primarily due to higher prices and sales volume of viscose products[15] - Operating profit for the reporting period was 36,567,001.17, compared to a loss of 133,711,045.78 in the same period last year, driven by increased gross margin from viscose products[15] - Net profit for the reporting period was 36,334,858.20, a significant improvement from a loss of 125,971,123.83 in the previous year[15] Cash Flow - The net cash flow from operating activities reached ¥197,519,222.99, compared to a negative cash flow of ¥262,259,246.41 in the same period last year, reflecting a 175.31% increase[7] - Cash received from sales of goods and services increased by 54% year-on-year, attributed to the rise in market prices and sales volume of viscose products[15] - Cash flow from operating activities decreased by 40% year-on-year, primarily due to a reduction in restricted cash payments[15] - The total cash outflow for operating activities was ¥952,945,396.90, compared to ¥1,298,254,825.76 in the same period last year[50] - The company’s cash flow from operating activities showed a net increase of ¥151,565,493.36 in Q1 2021, compared to ¥186,930,833.47 in the previous year[50] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,081,789,945.26, down 5.37% from ¥6,426,603,320.51 at the end of the previous year[7] - Total liabilities decreased to ¥5,077,152,581.44 from ¥5,458,300,814.89, reflecting a reduction in financial obligations[31] - The company's total equity increased to ¥1,004,637,363.82 from ¥968,302,505.62, showing a positive trend in shareholder value[32] - Short-term borrowings decreased to ¥1,674,020,531.65 from ¥1,823,998,836.02, indicating improved liquidity management[31] - Total current liabilities amounted to ¥4,456,305,734.41, down from ¥4,722,868,460.92, indicating better management of short-term obligations[31] Shareholder Information - The company had a total of 49,262 common shareholders at the end of the reporting period[11] - The largest shareholder, Aoyang Group Co., Ltd., held 30.31% of the shares, amounting to 235,349,599 shares, with 39,800,000 shares pledged[11] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] Other Income and Expenses - Non-recurring gains and losses totaled ¥35,705,198.63, primarily from non-current asset disposal gains and government subsidies[8] - Other income increased by 753% year-on-year, mainly due to increased government subsidies related to daily operations[15] - Financial expenses for Q1 2021 were CNY 34,404,521.57, down from CNY 45,536,254.79 in the previous year[38] Investment Activities - The company did not engage in any securities or derivative investments during the reporting period[18][19] - The company reported a significant increase in asset disposal gains of CNY 28,925,531.83 compared to a loss of CNY 84,217.95 in the previous period[39] - The company disposed of fixed assets and other long-term assets, recovering cash of ¥73,888,320.97 in Q1 2021, a significant increase from ¥645,079.14 in the previous year[51] Audit Status - The company has not undergone an audit for the Q1 2021 report, indicating that the figures presented are unaudited[53]

Financial Performance - The company's operating revenue for 2020 was approximately ¥3.08 billion, an increase of 3.40% compared to ¥2.98 billion in 2019[17]. - The net profit attributable to shareholders was approximately -¥459 million, a decrease of 7.95% from -¥425 million in 2019[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately -¥600 million, a decrease of 25.08% from -¥479 million in 2019[17]. - The net cash flow from operating activities was approximately ¥125 million, a significant increase of 119.97% compared to -¥628 million in 2019[17]. - The total assets at the end of 2020 were approximately ¥6.43 billion, an increase of 1.25% from ¥6.35 billion at the end of 2019[17]. - The net assets attributable to shareholders decreased by 32.52% to approximately ¥952 million from ¥1.41 billion at the end of 2019[17]. - The basic and diluted earnings per share were both -¥0.59, a decrease of 7.27% from -¥0.55 in 2019[17]. - The weighted average return on net assets was -38.84%, a decrease of 12.77% from -26.07% in 2019[17]. - The company reported a total of ¥38,399.95 million raised through non-public stock issuance, with ¥32,171.9 million utilized by the end of the reporting period[66]. - The company reported a net profit attributable to ordinary shareholders of -458,994,227.8 in 2020, with a profit distribution plan not proposed[80]. Revenue Breakdown - Total revenue for the year reached ¥3,083,401,180.95, with a quarterly breakdown showing Q1 at ¥634,283,585.15, Q2 at ¥713,235,700.51, Q3 at ¥784,459,238.10, and Q4 at ¥951,422,656.19[22]. - The chemical fiber segment generated revenue of approximately ¥1.21 billion, accounting for 39.38% of total revenue, with a year-on-year increase of 2.49%[42]. - The pharmaceutical logistics segment reported revenue of approximately ¥1.01 billion, representing 32.80% of total revenue, with a year-on-year increase of 6.53%[42]. - The medical service segment generated revenue of approximately ¥857.69 million, accounting for 27.82% of total revenue, with a year-on-year increase of 1.16%[42]. Operational Highlights - The company reported a total of 2,300 hospital beds across its medical service facilities, enhancing its healthcare service capacity[28]. - The company’s medical service business is expected to maintain stable profitability due to the growing demand for healthcare services in China, supported by the "14th Five-Year Plan"[29]. - The logistics subsidiary, Jiangsu Aoyang Pharmaceutical Logistics Co., has a total warehouse area of 32,000 square meters and serves over 8,000 downstream customers in the East China region[30]. - The company received government subsidies amounting to ¥25,543,197.04 in 2020, contributing to its financial performance[24]. - Aoyang Hospital was recognized as a tertiary comprehensive hospital in December 2020, enhancing the company's reputation in the healthcare sector[33]. Investment and Development - The company aims to strengthen its brand and expand its specialty services in the healthcare industry, focusing on information technology and operational efficiency[32]. - The company aims to establish a high-level research institute that integrates medical education and research, particularly in oncology, to enhance its service offerings[38]. - The company is enhancing its logistics capabilities through modernization and automation to improve service quality and efficiency[39]. - The company plans to enhance integrated development in healthcare and pharmaceutical sectors, focusing on optimizing asset adjustments and expanding non-insurance business[76]. - The company is exploring potential mergers and acquisitions to strengthen its market position[95]. Financial Stability and Risks - The company has no significant changes in major assets, indicating stability in its financial structure[31]. - The company has faced risks related to fluctuations in raw material prices and domestic and international demand[4]. - The company has recognized the need for potential support from the parent company to mitigate financial risks[189]. - Management identified significant liquidity risks and operational losses that could impact the company's ongoing viability[188]. - The asset-liability ratio was 84.53%, indicating substantial debt pressure, with financial liabilities due within 12 months amounting to 1.09 billion CNY, exceeding cash and cash equivalents of 463.61 million CNY[188]. Corporate Governance and Management - The company has maintained the same accounting firm, Lixin Accounting Firm, for 6 consecutive years, with an audit fee of 1.5 million yuan[88]. - The company has a strong emphasis on corporate governance, with independent directors ensuring oversight and accountability[145]. - The management team has a significant amount of experience in the industry, with many members holding multiple directorships in related sectors[145][148]. - The company has implemented a fair and effective performance evaluation system for senior management based on standardized management and operational efficiency[177]. - The company does not have any stock incentive plans for directors and senior management during the reporting period[159]. Environmental and Social Responsibility - The company actively participated in social responsibility activities, including free medical consultations in communities[116]. - The company has implemented all environmental protection facilities, with stable operation of wastewater and exhaust gas treatment systems[118]. - The daily wastewater treatment capacity of the company is 60,000 tons, meeting the national discharge standards[120]. - The company has established an emergency response plan for environmental incidents, effective from January 8, 2020[119]. - The company conducts automatic and manual monitoring of wastewater and exhaust gas, with specific parameters monitored regularly[120].